Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2913
OraDiscâ„¢ is a novel erodible muco-adhesive film product. This technology, known as OraDiscâ„¢, comprises a multi-layered film having an adhesive layer, a pre-formed film layer, and a coated backing layer. Depending upon the intended application, a pharmaceutically active compound can be formulated within any of these layers, providing a wide range of potential applications. The disc stays in place eroding over a period of time, so that subsequent removal is unnecessary. The drug delivery rate is pre-determined by the rate of erosion of the disc, which is in turn controlled by the composition of the backing layer. OraDiscâ„¢ was initially developed as a drug delivery system to treat canker sores with the same active ingredient (amlexanox) that is used in our AphthasolÂ® paste.
IPSCIO Record ID: 3211
Patent Applications shall mean United States non-provisional patent application U.S. Serial No. 10/713,544 filed in the USPTO, Europe, Canada, Mexico and Japan on November 14, 2003 and United States non-provisional patent application U.S. Serial No. 10/402,273 filed in the USPTO, Europe and Canada on March 28, 2003; all United States and foreign patents and patent applications deriving priority from the Provisional Applications, and any divisions, continuations, continuations-in-part, re-examinations and reissues of such patent applications.
IPSCIO Record ID: 203466
Licensor grants an exclusive, non-transferable, except in accordance with a permitted assignment of this Agreement, license in the Field to use Licensors trademark.
The Licensors trademark is ORADISC.
IPSCIO Record ID: 372482
For the Licensor Trademarks, Licensor grants an exclusive, including with respect to Licensor except as to Licensorâ€™s performance of its obligations under this Agreement and conduct of Existing Clinical Trials, license, with the right to sublicense, to use the Licensor Trademarks solely in connection with Product in the Territory.
Transmucosal delivery devices with enhanced uptake;
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces; and,
Transmucosal drug delivery for use in chronic pain relief.
Licensor controls certain patents and know-how relating to Product, and has initiated clinical studies with respect to the Product.
The Active Ingredient means buprenorphine. Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.
Product means a drug product containing buprenorphine as its sole active ingredient (and not containing naloxone or any analog or derivative thereof and using Licensors BEMA Technology in any formulation and any dosage strength.
BEMA Technology means Licensorâ€™s proprietary BioErodible MucoAdhesive (BEMAÂ®) Drug Delivery Technology, a buccal soluble film consisting of a small bioerodible polymer film for application to the mucosal membranes (inner lining of the cheek).